
- /
- Supported exchanges
- / US
- / CYBN.NYSE MKT
Cybin Inc (CYBN NYSE MKT) stock market data APIs
Cybin Inc Financial Data Overview
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cybin Inc data using free add-ons & libraries
Get Cybin Inc Fundamental Data
Cybin Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -134 963 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-01
- EPS/Forecast: -0.0248
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cybin Inc News

Canaccord Genuity lowers Cybin stock price target to $70 on model update
Investing.com - Canaccord Genuity lowered its price target on Cybin Inc. (NYSE:CYBN) to $70.00 from $73.00 on Tuesday, while maintaining a Buy rating following the company’s fiscal fourth-quarter ...


Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global...

Cybin reports Q4 results
* Cybin press release [https://seekingalpha.com/pr/20152717-cybin-reports-fiscal-year-2025-financial-results-and-recent-business-highlights] (NYSE:CYBN [https://seekingalpha.com/symbol/CYBN]): Q4 ...

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension stud...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.